EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
* Login for a full stack data experience
DATE
APR 2021
TABLES
105
PAGES
181
EDITION
8
PRICE
USD $4950
HIGHLIGHTS
SELECT PLAYERS
AstraZeneca PLC; Bristol-Myers Squibb Company; DelMar Pharmaceuticals, Inc.; Eisai Co., Ltd.; Emcure Pharmaceuticals Pvt., Ltd.; F. Hoffmann-La Roche AG; Fresenius Kabi Oncology Ltd.; ImmunoCellular Therapeutics Ltd.; iTeos Therapeutics SA; Kazia Therapeutics Ltd.; Merck & Co., Inc.; Moleculin Biotech, Inc.; Navinta LLC; NextSource Biotechnology, LLC; Northwest Biotherapeutics, Inc.; Novartis International AG; NovoCure Ltd. (Channel Islands); Tocagen, Inc.; United Technologies Corporation (UTC)
SEGMENTS
» Product (Cell-Based Products, Acellular Products) » Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Cell-Based Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cell-Based Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cell-Based Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Acellular Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Acellular Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Acellular Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
Rest of World Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 46 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com